Alogliptin
- Generic Name
- Alogliptin
- Brand Names
- Incresync, Kazano, Nesina, Oseni, Vipidia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N5O2
- CAS Number
- 850649-61-5
- Unique Ingredient Identifier
- JHC049LO86
- Background
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
- Indication
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 458
- Registration Number
- NCT05782192
- Locations
- 🇨🇳
1. Sun Yat-sen Memorial Hospital, Sun Yat-sen University,, Guangzhou, Guangdong, China
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 48
- Registration Number
- NCT05363592
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 48
- Registration Number
- NCT05363384
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Korea, Republic of
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3623
- Registration Number
- NCT04980040
Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 99
- Registration Number
- NCT04470310
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1293
- Registration Number
- NCT03794336
- Locations
- 🇨🇳
CHINA, China, China
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1026
- Registration Number
- NCT03555565
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 72
- Registration Number
- NCT03501277
- Locations
- 🇷🇺
Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways, Yaroslavl, Russian Federation
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Celltrion Pharm, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT03499704
- Locations
- 🇰🇷
The Catholic University of Korea, Bucheon, St. Marys Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, ST. Vincents Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 60
- Registration Number
- NCT03231709
- Locations
- 🇯🇵
OCROM Clinic, Suita, Osaka, Japan
🇯🇵ToCROM Clinic, Shinjuku, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.